title: Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3.
abstract: Access of four new tumor specific folic acid/ansamitocin conjugates is reported that relies on a synthetic strategy based on the combination of mutasynthesis and semisynthesis. Two bromo-ansamitocin derivatives were prepared by mutasynthesis or by a modified fermentation protocol, respectively, that served as starting point for the semisynthetic introduction of an allyl amine linker under Stille conditions. A sequence of standard coupling steps introduced the pteroic acid/glutamic acid/cysteine unit to the modified ansamitocins. All new derivatives, including those that are expected to be generated after internalization of the folic acid/ansamitocin conjugates into the cancer cell and reductive cleavage of the disulfide linkage showed good to strong antiproliferative activity (IC(50)  <10 nM) for different cancer cell lines. Finally, the four conjugates were exposed to two cancer cell lines [cervix carcinoma, KB-3-1 (FR+) and lung carcinoma, A-459 (FR-)], the latter devoid of the membrane-bound folic acid receptor (FR-). All four conjugates showed strong antiproliferative activity for the FR+ cancer cell line but were inactive against the FR- cell line. The synthetic strategy pursued is based on the combination of mutasynthesis and semisynthesis and proved to be powerful for accessing new ansamitocin derivatives that are difficult to prepare by total synthesis.
authors.affiliation: Institut für Organische Chemie und Biomolekulares Wirkstoffzentrum (BMWZ), Leibniz Universität Hannover, Schneiderberg 1B, 30167 Hannover, Germany.
authors.forename: Florian
authors.initials: F
authors.lastname: Taft
authors.forename: Kirsten
authors.initials: K
authors.lastname: Harmrolfs
authors.forename: Irinia
authors.initials: I
authors.lastname: Nickeleit
authors.forename: Anja
authors.initials: A
authors.lastname: Heutling
authors.forename: Miriam
authors.initials: M
authors.lastname: Kiene
authors.forename: Nisar
authors.initials: N
authors.lastname: Malek
authors.forename: Florenz
authors.initials: F
authors.lastname: Sasse
authors.forename: Andreas
authors.initials: A
authors.lastname: Kirschning
mesh_terms: D039903:Actinobacteria / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D058973:Folate Receptors, GPI-Anchored / Q000378:metabolism; D005492:Folic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D045325:HCT116 Cells; D006801:Humans; D020128:Inhibitory Concentration 50; D007624:KB Cells; D008297:Male; D008453:Maytansine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D051379:Mice; D019906:Nuclear Magnetic Resonance, Biomolecular; D048630:Polyketide Synthases / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D058973:Folate Receptors, GPI-Anchored; D008453:Maytansine; C015682:ansamitocins; D048630:Polyketide Synthases; D005492:Folic Acid